Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis

PURPOSE: Increased lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and Rho kinase activity may be associated with atherosclerosis. The principal aim of this study was to examine whether darapladib (a selective Lp-PLA2 inhibitor) could reduce the elevated Lp-PLA2 and Rho kinase activity in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Juan, Xu, Dong-Ling, Liu, Xiao-Bo, Bi, Shao-jie, Zhao, Tong, Sui, Shu-Jian, Ji, Xiao-Ping, Lu, Qing-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740522/
https://www.ncbi.nlm.nih.gov/pubmed/26847282
http://dx.doi.org/10.3349/ymj.2016.57.2.321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740522/
https://www.ncbi.nlm.nih.gov/pubmed/26847282
http://dx.doi.org/10.3349/ymj.2016.57.2.321

Ejemplares similares